Nxera Pharma Co., Ltd. (SOLTF)
OTCMKTS
· Delayed Price · Currency is USD
5.91
-0.49 (-7.66%)
Apr 23, 2025, 4:00 PM EDT
Nxera Pharma Revenue
In the year 2024, Nxera Pharma had annual revenue of 28.84B JPY with 125.87% growth. Nxera Pharma had revenue of 6.85B in the quarter ending December 31, 2024, a decrease of -6.03%.
Revenue
28.84B JPY
Revenue Growth
+125.87%
P/S Ratio
3.04
Revenue / Employee
77.10M JPY
Employees
374
Market Cap
557.93M USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.84B | 16.07B | 125.87% |
Dec 31, 2023 | 12.77B | -2.80B | -18.00% |
Dec 31, 2022 | 15.57B | -2.14B | -12.10% |
Dec 31, 2021 | 17.71B | 8.87B | 100.32% |
Dec 31, 2020 | 8.84B | -884.00M | -9.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SS Innovations International | 20.65M |
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Northwest Biotherapeutics | 1.38M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Nxera Pharma News
- 23 days ago - Nxera Pharma Announces Appointments to its Executive Leadership Team - GlobeNewsWire
- 4 weeks ago - Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder - GlobeNewsWire
- 7 weeks ago - Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan - GlobeNewsWire
- 2 months ago - Nxera Pharma Proposes Changes to its Board of Directors - GlobeNewsWire
- 2 months ago - Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 3 months ago - Nxera Pharma Webinar Presentation for FY2024 Financial Results - GlobeNewsWire
- 3 months ago - Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewsWire
- 4 months ago - Nxera Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire